RhinoCyte
Founded Year
2005Stage
Convertible Note | AliveTotal Raised
$4.69MLast Raised
$250K | 7 yrs agoAbout RhinoCyte
RhinoCyte is a biotechnology company that has developed a method of isolating adult stem cells located in the olfactory regions of the mucosal lining of the human nasal passageway, which can be used in therapies for spinal cord injury, multiple sclerosis, ALS and Parkinson's Disease.
Missing: RhinoCyte's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: RhinoCyte's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing RhinoCyte
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
RhinoCyte is included in 2 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
RhinoCyte Frequently Asked Questions (FAQ)
When was RhinoCyte founded?
RhinoCyte was founded in 2005.
Where is RhinoCyte's headquarters?
RhinoCyte's headquarters is located at 1044 E. Chestnut Street, Louisville.
What is RhinoCyte's latest funding round?
RhinoCyte's latest funding round is Convertible Note.
How much did RhinoCyte raise?
RhinoCyte raised a total of $4.69M.
Who are the investors of RhinoCyte?
Investors of RhinoCyte include Kentucky Seed Capital Fund, Queen City Angels, Triathlon Medical Venture Partners, Mammoth View, Bluegrass Angels and 3 more.
Who are RhinoCyte's competitors?
Competitors of RhinoCyte include Noveome Biotherapeutics, Molmed, NGM Biopharmaceuticals, ISTO Technologies, Cellerant Therapeutics and 12 more.
Compare RhinoCyte to Competitors
Animal Cell Therapies is a biotech firm that aims to improve the lives of animals through thoughtful research and development. The ACT team is focused on developing and delivering cellular treatment and services to customers.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
Minerva Biotechnologies developd biochips: nanoparticles coated with functionalized affinity surfaces. Minerva has developed user-friendly nanoparticles that the end user can utilize as a "black box technology". The nanoparticle system can be fully automated and a range of nanoparticles have been developed so that the readout is compatible with existing lab equipment.
Cell Line Genetics aims to provide services and products to support research institutions, as well as biotechnology and pharmaceutical companies focused on embryonic stem cell and cancer research.
ARI is developing biotechnology solutions to the pervasive problem of hair loss. This cell therapy and tissue engineering research focuses on developing hair follicle progenator tissue for cosmetic hair replacement surgery. Safe and effective tissue engineered products will be developed based upon the molecular and cellular mechanisms of hair growth and multiplicati. ARI was created by Aderans Co., of Tokyo, Japan and its US Susidiary Bosley, the World's largest hair restoration practice. The company was formerly known as BioAmide .
Enox Biopharma is a biotechnology company that developed a drug eluting technology suitable for treatment of acute and antibiotic resistant ear infection in children.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.